Human immunodefidency virus (HIV) - Specific cellular immune responses in newborns exposed to HIV in utero

Clinical Infectious Diseases

Volumn 34, Issue 2, 2002, Pages 267-276

  Kuhn, Louise ^a   Meddows Taylor, Stephen ^b   Gray, Glenda ^c   Tiemessen, Caroline ^b  

^a Taub Institute for Research on Alzheimer's Disease and the Aging Brain and the Gertrude H Sergievsky Center   (United States)

^b NATIONAL INSTITUTE FOR COMMUNICABLE DISEASES   (South Africa)

^c UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; INTERLEUKIN 2;

ARTICLE; ASSAY; BLOOD CELL; BREAST FEEDING; CELL PROLIFERATION; CELLULAR IMMUNITY; CYTOKINE PRODUCTION; CYTOTOXIC T LYMPHOCYTE; HELPER CELL; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; NEWBORN; PRENATAL EXPOSURE; PRIORITY JOURNAL; VIRUS TRANSMISSION; DISEASE TRANSMISSION; FEMALE; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; PREGNANCY; PREGNANCY COMPLICATION; REVIEW;

BREAST FEEDING; DISEASE TRANSMISSION, VERTICAL; FEMALE; HIV INFECTIONS; HUMAN; IMMUNITY, CELLULAR; INFANT, NEWBORN; PREGNANCY; PREGNANCY COMPLICATIONS, INFECTIOUS;

EID: 0037079562     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/338153     Document Type: Article

References (109)

1. Immune responses in HIV-exposed seronegatives: Have they repelled the virus?
2. Protective immunity against HIV infection: Has nature done the experiment for us?
3. Lymphocyte proliferative responses to HIV-1 envelope and core antigens by infected and uninfected adults and children
4. Cytotoxic T lymphocyte responses in the peripheral blood of children born to human immunodeficiency virus-l-infected mothers
5. HIV-specific cytotoxic T-cell activity in an HIV-exposed but uninfected infant
6. Cytotoxic T lymphocyte activity and CD8 subpopulations in children at risk of HIV infection
7. Occurrence of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T cell activity in apparently uninfected children born to HIV-l-infected mothers
8. High frequency of Gag- and envelope-specific cytotoxic T lymphocyte precursors in children with vertically acquired human immunodeficiency virus type 1 infection
9. HIV-l-specific cytotoxic T lymphocyte responses in the first year of life
10. Cellular immune factors associated with mother-to-infant transmission of HIV
11. T-helper cell responses to HIV envelope peptides in cord blood: Protection against intrapartum and breastfeeding transmission
12. Protective role of β-chemokines associated with HIV-specific Th responses against perinatal HIV transmission
13. T-lymphocyte maturation abnormalities in uninfected newborns and children with vertical exposure to HIV
14. C-C chemokines, pivotal in protection against HIV type 1 infection
15. CD8 cell noncytotoxic antiviral activity in human immunodeficiency virus-infected and -uninfected children
16. Continuous clearance of HIV in a vertically infected child
17. Clearance of HIV infection in 12 perinatally infected children: Clinical, virological and immunological data
18. Repeatedly positive human immunodeficiency virus type 1 DNA polymerase chain reaction in human immunodeficiency virus-exposed seroreverting infants
19. Detection of virus in vertically exposed HIV-antibody negative children
20. Clearance of HIV infection in a perinatally infected infant
21. Genetic evaluation of suspected cases of transient HIV-1 infection of infants
22. + lymphocytes in healthy infants and early lymphocyte activation in uninfected infants of human immunodeficiency virus-infected mothers
23. Correlation of virus load and soluble L-selectin, a marker of immune activation, in pediatric HIV-1 infection
24. + T cells during the early phase of pediatric human immunodeficiency virus infection: Characterization of expanded cell populations by T cell receptor phenotyping
25. Influence of human immunodeficiency virus-infected maternal environment on development of infant interleukin-12 production
26. Interferon-gamma and interleukin-10 production among HIV-l-infected and uninfected infants of HIV-l-infected mothers
27. Cytotoxic-T-cell responses, viral load, and disease progression in early human immunodeficiency virus type 1 infection
28. Association between virus-specific cytotoxic T-lymphocyte and helper responses in human immunodeficiency virus type 1 infection
29. Association between HIV-specific T helper responses and CTL activities in pediatric AIDS
30. Diminished HIV-specific CTL activity is associated with lower type 1 and enhanced type 2 responses to HIV-specific peptides during perinatal HIV infection
31. + T cell responses associated with control of viremia
32. + T cells are detectable in most individuals with active HIV-1 infection, but decline with prolonged viral suppression
33. Lymphoproliferative response to HIV type 1 p24 in long-term survivors of HIV type 1 infection is predictive of persistent AIDS-free infection
34. Early and persistent human immunodeficiency virus type 1 (HIV-1)-specific T helper dysfunction in blood and lymph nodes following acute HIV-1 infection
35. Helper T-cell responses in children infected with human immunodeficiency virus type 1
36. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease
37. + T cell subset phenotyping independently predict survival time in patients infected with human immunodeficiency virus
38. Role of cellular immunity in protection against HIV infection
39. Timing of maternal-infant HIV transmission: Associations between intrapartum factors and early polymerase chain reaction results
40. Proposed definitions for in utero versus intrapartum transmission of HIV-1
41. Interleukin-2 production used to detect antigenic peptide recognition by T-helper Iymphocytes from asymptomatic HIV-seropositive individuals
42. Construction of peptides encompassing multideterminant clusters of human immunodeficiency virus envelope to induce in vitro T cell responses in mice and humans of multiple MHC types
43. T cell multideterminant regions in the human immunodeficiency virus envelop: Toward overcoming the problem of major histocompatibility complex restriction
44. Helper T-cell antigenic site identification in the acquired immunodeficiency syndrome virus gp120 envelop protein and induction of immunity in mice to the native protein using a 16-residue synthetic peptide
45. Sensitivity of HIV-1 DNA polymerase chain reaction in the neonatal period
46. Timing of mother-to-child HIV-1 transmission and diagnosis of infection based on polymerase chain reaction in the neonatal period by a non-parametric method
47. Defining the time of fetal or perinatal acquisition of human immunodeficiency virus type 1 infection on the basis of age at first positive culture
48. Cell-mediated immune response to human immunodeficiency virus (HIV) type 1 in seronegative homosexual men with recent sexual exposure to HIV-1
49. Exposure to human immunodeficiency virus type 1-specific T helper cell responses before detection of infection by polymerase chain reaction and serum antibodies
50. Human immunodeficiency virus type 1 (HIV-1)-seronegative injection drug users at risk for HIV exposure have antibodies to HLA class I antigens and T cells specific for HIV envelop
51. T-cell response towards HIV in infected individuals with and without zidovudine therapy, and in HIV-exposed sexual partners
52. Lymphocytes from some long-term seronegative heterosexual partners of HIV-infected individuals proliferate in response to HIV antigens
53. Human immunodeficiency virus (HIV) nef-specific cytotoxic T lymphocytes in noninfected heterosexual contact of HIV-infected patients
54. High prevalence of HIV-specific immunity in seronegative Ethiopian immigrants in Israel
55. +) T cells from exposed uninfected individuals expressing the wild-type CCR-5 allele
56. + T lymphocytes responsive to human immunodeficiency virus (HIV) peptide antigens in HIV-infected patients and seronegative persons at high risk for recent HIV exposure
57. +) cell noncytotoxic anti-HIV response
58. Human Immunodeficiency virus (HIV)-specific cytotoxic T lymphocyte activity in HIV-exposed seronegative persons
59. Protection against human immunodeficiency virus type 1 infection in persons with repeated exposure: Evidence for T cell immunity in the absence of inherited CCR5 coreceptor defects
60. Factors contributing to the lack of human immunodeficiency virus type 1 (HIV-1) transmission in HIV-l-discordant partners
61. Sensitization to human immunodeficiency virus in seronegative exposed partners
62. Resistance to HIV-1 infection among persistently seronegative prostitutes in Nairobi, Kenya
63. HIV-l-specific cellular immune responses among HIV-l-resistant sex workers
64. HIV-specific cytotoxic T-cells in HIV-exposed but uninfected Gambian women
65. Cytotoxic T cell responses to multiple conserved HIV epitopes in HIV-resistant prostitutes in Nairobi
66. HIV-specific T-helper activity in seronegative health care workers exposed to contaminated blood
67. ENV-specific cytotoxic T lymphocyte responses in HIV seronegative health care workers occupationally exposed to HIV-contaminated body fluids
68. HIV-specific mucosal and cellular immunity in HIV-seronegative partners of HIV-seropositive individuals
69. HlV-l-specific mucosal IgA in a cohort of HIV-l-resistant Kenyan sex workers
70. Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women
71. Epidemiologic and biologic characterization of a cohort of human immunodeficiency virus type 1 highly exposed, persistently seronegative female sex workers in northern Thailand
72. + lymphocyte responses in the cervix of HIV-l-resistant prostitutes in Nairobi
73. Frequent and early in utero HIV-1 infection
74. Excess intrauterine fetal demise associated with maternal human immunodeficiency virus infection
75. Fetal human immunodeficiency virus type 1 infection of different organs in the second trimester
76. Maternofetal transmission of AIDS: Frequency of human immunodeficiency virus type 1 nucleic acid sequences in human fetal DNA
77. Human immunodeficiency virus type 1 infection of human placenta: Potential route for fetal infection
78. Human immunodeficiency virus type 1 infection of human placental macrophages in vitro
79. HIV-1 proviral DNA polymerase chain reaction detection in chorionic villi after exclusion of maternal contamination by variable number of tandem repeats analysis
80. Selection of maternal human immunodeficiency virus type 1 variants in human placenta. European Network for In Utero Transmission of HIV-1
81. Presence of human immunodeficiency virus (HIV) type 1 and HIV-l-specific antibodies in cervicovaginal secretions of infected mothers and in the gastric aspirates of their infants
82. Intrapartum mucosal exposure to human immunodeficiency virus type 1 (HIV-1) of infants born to HIV-l-infected mothers correlates with maternal plasma virus burden
83. Frequent detection of HIV-1 in the gastric aspirates of neonates born to HIV-infected mothers
84. Exposure to HIV-1 during delivery and mother-to-child transmission
85. T-cell proliferation to subinfectious SIV correlates with lack of infection after challenge of macaques
86. Mother-child class I HLA concordance increases perinatal human immunodeficiency virus type 1 transmission
87. Reduction of maternal-infant transmission of human immunodeficiency virus type 1 with zidovudine treatment
88. Short-course zidovudine for perinatal HIV-1 transmission in Bangkok, Thailand: A randomized controlled trial
89. Short-course oral zidovudine for prevention of mother-to-child transmission of HIV-1 in Abidjan, Côte D'Ivoire: A randomized trial
90. 6-Month efficacy, tolerance, and acceptability of a short regimen of oral zidovudine to reduce vertical transmission of HIV in breast fed children in Côte d'Ivoire and Burkina Faso: A double-blind placebo-controlled multicentre trial
91. Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant
92. Reduced HIV-stimulated T-helper cell reactivity in cord blood with short-course antiretroviral treatment for prevention of maternal-infant transmission
93. Effect of zidovudine postexposure prophylaxis on the development of HIV-specific cytotoxic T-lymphocyte responses in HIV-exposed healthcare workers
94. Early therapy of vertical human immunodeficiency virus type 1 (HIV-1) infection: Control of viral replication and absence of persistent HIV-l-specific immune responses
95. Immune control of HIV-1 after early treatment of acute infection
96. Enhancement of human immunodeficiency virus type l-specific CD4 and CD8 T cell responses in chronically infected persons after temporary treatment interruption
97. + T cell responses in a cohort of chronically infected patients are associated with interruptions in anti-HIV chemotherapy
98. Developmental immunology and role of host defences in neonatal susceptibility to infection
99. Analysis of T helper and antigen-presenting cell functions in cord blood and peripheral blood leukocytes from healthy children of different ages
100. Analysis of neonatal T cell and antigen presenting cell functions
101. Analysis of the cytokine production by cord and adult blood
102. T-cell function in newborn mice and humans
103. Induction of protective CTL responses in newborn mice by a murine retrovirus
104. Demonstration of human T lymphotropic virus type I (HTLV-I-specific T cell responses from seronegative and polymerase chain reaction-negative persons exposed to HTLV-I
105. Hepatitis C virus-specific cytolytic T lymphocyte and T helper cell responses in seronegative persons
106. Lymphocyte reactivity to hepatitis C virus (HCV) antigens shows evidence for exposure to HCV in HCV-seronegative spouses of HCV-infected patients
107. Safety and immunogenicity of HIV recombinant envelope vaccines in HIV-infected infants and children
108. Lymphoproliferative responses to recombinant HIV-1 envelope antigens in neonates and infants receiving gpl20 vaccines
109. Safety of 2 recombinant human immunodeficiency virus type 1 (HIV-1) envelope vaccines in neonates born to HIV-l-infected women